Lynx1 Capital Management

Latest statistics and disclosures from Lynx1 Capital Management's latest quarterly 13F-HR filing:

Tip: Access up to 7 years of quarterly data

Positions held by Lynx1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Lynx1 Capital Management

Lynx1 Capital Management holds 16 positions in its portfolio as reported in the March 2024 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Alpine Immune Sciences (ALPN) 23.0 $89M -40% 2.3M 39.64
 View chart
Merus N V (MRUS) 17.5 $68M +32% 1.5M 45.03
 View chart
Stoke Therapeutics (STOK) 12.9 $50M +25% 3.7M 13.50
 View chart
Tscan Therapeutics (TCRX) 10.7 $42M 5.2M 7.94
 View chart
Cabaletta Bio (CABA) 9.2 $36M 2.1M 17.06
 View chart
Gh Research Ordinary Shares (GHRS) 9.1 $35M +80% 3.3M 10.66
 View chart
C4 Therapeutics Com Stk (CCCC) 7.6 $30M +15% 3.6M 8.17
 View chart
Silence Therapeutics Ads (SLN) 2.9 $11M +123% 527k 21.60
 View chart
Autolus Therapeutics Spon Ads (AUTL) 2.3 $8.9M -25% 1.4M 6.38
 View chart
Passage Bio (PASG) 1.7 $6.5M +1178% 4.8M 1.35
 View chart
Kinnate Biopharma (KNTE) 1.4 $5.3M 2.0M 2.66
 View chart
Ibio Con New (IBIO) 0.6 $2.4M NEW 600k 4.06
 View chart
Nektar Therapeutics (NKTR) 0.5 $1.9M +7% 2.1M 0.93
 View chart
Pieris Pharmaceuticals (PIRS) 0.4 $1.6M -10% 8.8M 0.18
 View chart
Bionomics Ads (BNOX) 0.2 $839k 815k 1.03
 View chart
Centessa Pharmaceuticals Sponsored Ads (CNTA) 0.1 $197k NEW 17k 11.30
 View chart

Past Filings by Lynx1 Capital Management

SEC 13F filings are viewable for Lynx1 Capital Management going back to 2021